Callisto is a biopharmaceutical company focused primarily on the development of Atiprimod, an orally administered drug with antiproliferative, anti-inflammatory and antiangiogenic activity, to treat rheumatoid arthritis (RA). Atiprimod earlier completed a Phase II clinical trial in advanced carcinoid cancer, a neuroendocrine tumor, and, subsequent to this, further development was redirected towards treatment of RA. Callisto's second drug, L-Annamycin, is a member of the anthracycline family, with a novel therapeutic profile including activity against drug resistant tumors. L-Annamycin completed a Phase I clinical trial in adult relapsed or refractory acute lymphocytic leukemia patients.
View Top Employees from Callisto Pharmaceuticals , Inc.| Website | http://www.callistopharma.com |
| Revenue | $2 million |
| Employees | View employees |
| Address | 420 Lexington Ave, Ste 1609, New York City, New York 10170, US |
| Phone | (212) 297-0170 |
| Fax | (212) 297-0190 |
| Industry | Manufacturing General, Manufacturing |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies |
Looking for a particular Callisto Pharmaceuticals , Inc. employee's phone or email?
Callisto Pharmaceuticals , Inc. Questions
The Callisto Pharmaceuticals , Inc. annual revenue was $2 million in 2024.
Callisto Pharmaceuticals , Inc. is based in New York City, New York.
The NAICS codes for Callisto Pharmaceuticals , Inc. are [3254, 325, 32541, 32].
The SIC codes for Callisto Pharmaceuticals , Inc. are [283, 28].
